ATE526411T1 - Avirulente, immunogene flavivirus-chimäre - Google Patents

Avirulente, immunogene flavivirus-chimäre

Info

Publication number
ATE526411T1
ATE526411T1 AT01910882T AT01910882T ATE526411T1 AT E526411 T1 ATE526411 T1 AT E526411T1 AT 01910882 T AT01910882 T AT 01910882T AT 01910882 T AT01910882 T AT 01910882T AT E526411 T1 ATE526411 T1 AT E526411T1
Authority
AT
Austria
Prior art keywords
chimeric viruses
chimeric
avirulent
flavivirus
flaviviruses
Prior art date
Application number
AT01910882T
Other languages
English (en)
Inventor
Richard Kinney
Claire Kinney
Siritorn Butrapet
Duane Gubler
Natth Bhamarapravati
Original Assignee
Us Gov Health & Human Serv
Univ Mahidol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Univ Mahidol filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE526411T1 publication Critical patent/ATE526411T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01910882T 2000-02-16 2001-02-16 Avirulente, immunogene flavivirus-chimäre ATE526411T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18282900P 2000-02-16 2000-02-16
PCT/US2001/005142 WO2001060847A2 (en) 2000-02-16 2001-02-16 Avirulent, immunogenic flavivirus chimeras

Publications (1)

Publication Number Publication Date
ATE526411T1 true ATE526411T1 (de) 2011-10-15

Family

ID=22670221

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01910882T ATE526411T1 (de) 2000-02-16 2001-02-16 Avirulente, immunogene flavivirus-chimäre

Country Status (10)

Country Link
US (6) US7094411B2 (de)
EP (3) EP2278012B1 (de)
JP (1) JP4656794B2 (de)
AT (1) ATE526411T1 (de)
AU (4) AU3844101A (de)
CA (2) CA2941182A1 (de)
DK (1) DK2278012T3 (de)
ES (2) ES2374131T3 (de)
PT (1) PT2278012E (de)
WO (1) WO2001060847A2 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
DK2278012T3 (en) * 2000-02-16 2015-12-07 Us Government Immunogenic dengue 2 virus chimeras
AU2002211490A1 (en) * 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
AT410634B (de) * 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
CN100392087C (zh) * 2001-11-26 2008-06-04 昆士兰大学 黄病毒疫苗输送系统
EP1456230A2 (de) * 2001-12-04 2004-09-15 Bavarian Nordic A/S Impfstoff aus der ns1-untereinheit eines flavivirus
CA2472468C (en) * 2002-01-10 2015-11-24 Alexander G. Pletnev Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
AU2013213749A1 (en) * 2002-01-10 2013-08-29 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
JP2005519639A (ja) 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
US7459297B2 (en) 2003-05-30 2008-12-02 Centre National De La Recherche Scientifique -Cnrs Active truncated form of the RNA polymerase of flavivirus
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7749734B2 (en) 2004-12-24 2010-07-06 The Research Foundation For Microbial Diseases Of Osaka University Attenuated chimeric flavivirus bearing attenuated Japanese encephalitis virus gene as backbone
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006134433A1 (en) * 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
US7455842B2 (en) * 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
CN101400790A (zh) * 2006-03-13 2009-04-01 学校法人庆应义塾 流感感染抑制肽、流感病毒感染抑制剂、脂质体、流感预防或治疗剂
AR061197A1 (es) * 2006-06-07 2008-08-13 Sanofi Pasteur Cepas del virus 3 del dengue vivas atenuadas
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
TW200827442A (en) * 2006-11-03 2008-07-01 Nat Health Research Institutes Method for amplifying a flavivirus cDNA in a prokaryotic cell
CN101808657A (zh) * 2006-11-07 2010-08-18 赛诺菲巴斯德生物制剂公司 冻干法稳定疫苗
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
HUE031617T2 (en) * 2007-04-06 2017-07-28 Takeda Vaccines Inc Methods and compositions for live attenuated viruses
RU2527891C2 (ru) * 2007-05-07 2014-09-10 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Флавивирус с двухкомпонентным геномом и его использование
CN101855349A (zh) * 2007-11-07 2010-10-06 日本国立感染症研究所 西尼罗病毒疫苗及其生产方法
CN105944095B (zh) 2008-03-05 2021-04-02 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
US8715689B2 (en) * 2008-04-30 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
WO2009152147A2 (en) * 2008-06-09 2009-12-17 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
EP2143440A1 (de) 2008-07-09 2010-01-13 Sanofi Pasteur Stabilisierungssubstanz und Impfzusammensetzung, die ein oder mehrere abgeschwächte lebende Flaviviridae enthält
BR122020015754B8 (pt) * 2008-12-05 2021-04-06 Takeda Vaccines Inc métodos para aumentar a taxa de crescimento viral, para aumentar o tamanho da placa de uma cultura viral, para reduzir o tempo de latência do crescimento de uma cultura viral, e para a cultura de vírus para a produção e fabricação
WO2010138885A2 (en) 2009-05-28 2010-12-02 The United States Of America, S.A., As Represented By The Secretary, Department Of Health And Human Services Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN102449172A (zh) * 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法
AU2010286368B2 (en) * 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (de) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunisierungszusammensetzungen und -verfahren
US10238734B2 (en) 2010-03-23 2019-03-26 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US8685649B2 (en) * 2010-06-10 2014-04-01 The United States Of America As Represented By The Secretary Of The Navy RT-LAMP assay for the detection of pan-serotype dengue virus
US10308689B2 (en) 2010-06-24 2019-06-04 La Jolla Institute For Allergy And Immunology Dengue virus (DV) polypeptide sequences, T cell epitopes and methods and uses thereof
US20120294889A1 (en) * 2010-11-12 2012-11-22 Paxvax, Inc. Chimeric Flavivirus Vaccines
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
KR20150036592A (ko) 2012-07-24 2015-04-07 사노피 파스퇴르 백신 조성물
TW201920677A (zh) * 2012-11-08 2019-06-01 美商武田疫苗股份有限公司 登革熱病毒血清型4型之建構物的組成物、方法及用途
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
EP2931310A4 (de) 2012-12-14 2016-05-25 Takeda Vaccines Inc Zusammensetzungen, verfahren zur verabreichung und verwendungen für dreiwertige dengue-virus-formulierungen
CA3177574C (en) * 2013-03-15 2026-03-31 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for dengue virus chimeric constructs in vaccines
US9695421B2 (en) 2013-07-05 2017-07-04 Bioneer Corporation Dengue virus-specific siRNA, double helix oligo-RNA structure comprising siRNA, and composition for suppressing proliferation of dengue virus comprising RNA structure
US10046045B2 (en) 2013-12-20 2018-08-14 The Regents Of The University Of Michigan Vaccine compositions and uses thereof
EP3158061B1 (de) 2014-06-20 2019-08-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Chimäre west-nil/dengue-viren und verfahren zur verwendung
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
AU2016210835B2 (en) * 2015-01-29 2021-01-21 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
EP3316905A1 (de) 2015-07-03 2018-05-09 Sanofi Pasteur Gleichzeitige impfung gegen dengue und gelbfieber
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
US10655110B2 (en) * 2015-11-27 2020-05-19 Km Biologics Co., Ltd. Multivalent dengue vaccine composition comprising a mixture of attenuated dengue viruses from different serotypes
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
WO2018009604A1 (en) 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
JP7117015B2 (ja) * 2016-11-28 2022-08-12 メディジェン, インコーポレイテッド プラス鎖rnaウイルスによって引き起こされる感染疾患に対するワクチン
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
BR112019021872A2 (pt) 2017-04-26 2020-06-02 F. Hoffmann-La Roche Ag Polipeptídeo, método de produção de um polipeptídeo, métodos para detectar anticorpos, usos de um polipeptídeo e kits de reagentes
EP3681514A4 (de) 2017-09-14 2021-07-14 ModernaTX, Inc. Rna-vakzine gegen zika-virus
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
US11702453B2 (en) 2018-08-21 2023-07-18 Regents Of The University Of Michigan Materials and methods for inhibiting flavivirus infection
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11590221B2 (en) 2018-09-05 2023-02-28 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
EP4010355A4 (de) * 2019-08-06 2024-02-21 The University of North Carolina at Chapel Hill Verfahren und zusammensetzungen für stabilisierte rekombinante flavivirus-e-protein-dimere
US20240076631A2 (en) 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
US12318439B2 (en) * 2021-05-09 2025-06-03 Board Of Regents, The University Of Texas System Attenuating viral mutations in protein genes
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
EP4519847A1 (de) 2022-05-04 2025-03-12 Takeda Vaccines, Inc. Computerbasierte bestimmung der flavivirus-infektivität
CN120225693A (zh) 2022-11-18 2025-06-27 武田疫苗股份有限公司 测定制剂中具有包含至少一个减毒基因座的核苷酸序列的活减毒黄病毒的比例的方法
EP4626574A1 (de) 2022-11-29 2025-10-08 Takeda Vaccines, Inc. Herstellung und herstellung eines flavivirusimpfstoffs im grossmassstab
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells
WO2026050432A1 (en) * 2024-08-27 2026-03-05 Vaccine Company, Inc. Engineered flavivirus antigens and uses thereof
WO2026077983A1 (en) 2024-10-08 2026-04-16 Sanofi R&D Vaccins Compositions and methods for stabilizing live-attenuated flaviviruses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276941A (en) 1975-12-23 1977-06-28 Ito Masato Method of conversing infrared rays
JPH0768267B2 (ja) 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
EP0872553B1 (de) * 1991-09-19 2000-11-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES Chimäre und/oder wachstumgehemmte Flaviviren
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
DE69624815T2 (de) 1995-05-24 2003-07-10 Hawaii Biotech Group Untereinheitsimpfstoff gegen flavivirus infektion
WO1996040933A1 (en) * 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
EP1021544B1 (de) * 1997-10-08 2005-12-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Chimärer impfstoff gegen das zeckenenzephalitis virus
WO1999063095A1 (en) 1998-06-04 1999-12-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection
DK2278012T3 (en) * 2000-02-16 2015-12-07 Us Government Immunogenic dengue 2 virus chimeras
US6441262B1 (en) * 2001-02-16 2002-08-27 Exxonmobil Chemical Patents, Inc. Method for converting an oxygenate feed to an olefin product
US20030148261A1 (en) 2001-03-12 2003-08-07 Erol Fikrig Compositions and methods comprising West Nile virus polypeptides
WO2002072035A2 (en) 2001-03-14 2002-09-19 Lipogenics, Inc. Novel anti-inflammatory compositions and methods of use
JP5276941B2 (ja) 2008-09-24 2013-08-28 株式会社村田製作所 大変位アクチュエータ
WO2018009604A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines

Also Published As

Publication number Publication date
JP4656794B2 (ja) 2011-03-23
AU3844101A (en) 2001-08-27
EP2278012A3 (de) 2011-03-09
AU2007200319A1 (en) 2007-02-15
US8025887B2 (en) 2011-09-27
US20160367658A1 (en) 2016-12-22
US9463233B2 (en) 2016-10-11
US20140141040A1 (en) 2014-05-22
US10335478B2 (en) 2019-07-02
US20100255030A1 (en) 2010-10-07
EP1263965B1 (de) 2011-09-28
AU2009212794A1 (en) 2009-09-17
EP2278012B1 (de) 2015-08-26
CA2941182A1 (en) 2001-08-23
CA2398872A1 (en) 2001-08-23
AU2007200319B8 (en) 2010-01-07
AU2007200319B2 (en) 2009-05-28
US7094411B2 (en) 2006-08-22
WO2001060847A2 (en) 2001-08-23
EP1263965A2 (de) 2002-12-11
JP2003523189A (ja) 2003-08-05
EP3000477A1 (de) 2016-03-30
EP2278012A2 (de) 2011-01-26
US8673316B2 (en) 2014-03-18
WO2001060847A9 (en) 2002-10-17
AU2009212794B2 (en) 2012-02-09
US20090010961A1 (en) 2009-01-08
WO2001060847A3 (en) 2002-04-25
ES2554254T3 (es) 2015-12-17
ES2374131T3 (es) 2012-02-14
US20060062803A1 (en) 2006-03-23
DK2278012T3 (en) 2015-12-07
US20120014981A1 (en) 2012-01-19
CA2398872C (en) 2018-03-20
PT2278012E (pt) 2015-11-30
US7641909B2 (en) 2010-01-05
AU2001238441B2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
AU3844101A (en) Avirulent, immunogenic flavivirus chimeras
Bråve et al. Vaccine delivery methods using viral vectors
JP2026040566A (ja) SARS-CoV-2ワクチン
ES2662030T3 (es) Sistema de construcciones y usos para el mismo
WO2018081318A1 (en) Prefusion coronavirus spike proteins and their use
ES2337893T3 (es) Vacuna del virus del nilo occidental.
JP2010057496A (ja) キメラフラビウイルスワクチン
ES2546330T3 (es) Composición de vacuna
JP2009504654A (ja) デングウイルス感染に対するワクチン接種
Hajam et al. Co-administration of flagellin augments immune responses to inactivated foot-and-mouth disease virus (FMDV) antigen
JP7721604B2 (ja) ネコカリシウイルスワクチン
ES2745431T3 (es) Composiciones para vacunas contra el virus del dengue y su uso
US20240350619A1 (en) Vaccines and compositions based on sars-cov-2 s protein
EP3608332B1 (de) Impfstoff gegen humanes rhinovirus
AU2018200081B2 (en) Avirulent, immunogenic flavivirus chimeras
ES2637629T3 (es) Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
ES2260754T3 (es) Metodo para producir un conjunto de antigenos polipeptidicos combinatorios.
Farnós et al. The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice
CA2828068A1 (en) Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
Lu et al. Enhanced protective immune response of foot-and-mouth disease vaccine through DNA-loaded virus-like particles
Xie et al. Advances in vaccinia virus-based vaccine vectors, with applications in flavivirus vaccine development
AU2019362276A1 (en) Virus vaccine
JP2011088864A (ja) インフルエンザウイルスに対するベクターワクチン
Tafuku et al. Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice
ES2267510T3 (es) Acidos nucleicos y polipeptidos de lisavirus quimericos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1263965

Country of ref document: EP